Alpha-Defensin vs Retatrutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Alpha-Defensin
Alpha-defensins are small cationic peptides that are key components of the innate immune system. They have broad-spectrum antimicrobial activity against bacteria, fungi, and some viruses.
Full details →Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Side-by-Side Comparison
| Aspect | Alpha-Defensin | Retatrutide |
|---|---|---|
| Mechanism | Insert into microbial membranes to form pores, leading to cell death. Also have immunomodulatory effects including chemotaxis of immune cells and cytokine modulation. | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. |
| Typical Dosage | Research compound - dosing varies by application. Typically studied in laboratory and early clinical research settings rather than for general use. | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. |
| Administration | Various routes studied including topical, local injection, and systemic administration depending on application. | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. |
| Side Effects | Limited human use data. May cause local inflammation. Potential for immune activation effects. | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. |
| Best For |